Ticker Launch
Sign inTry it free

SPAC · Deal announced

Bowen Acquisition Corp

Business combination with Shenzhen Qianzhi BioTechnology Co. Ltd.

Bowen Acquisition Corp is a blank-check company (SPAC) that raised $60M in its initial public offering on Jul 12, 2023, listing on Nasdaq Global Market. It agreed to combine with Shenzhen Qianzhi BioTechnology Co. Ltd., announced on Jan 18, 2024. The deal has not closed yet. PROPOSED BUSINESS Our Company led the IPO. Graubard Miller advised the SPAC and Winston & Strawn advised the underwriters on the IPO.

Shenzhen Qianzhi BioTechnology Co. Ltd. is a Shenzhen, China-based health and wellness biotechnology company. It develops plant-based and ozonated products for antibacterial, skincare, gynecological and andrological applications.

Status
Deal announced
IPO date
Jul 12, 2023
IPO size
$60M
IPO exchange
Nasdaq Global Market
Target
Shenzhen Qianzhi BioTechnology Co. Ltd.
Target sector
Biotech
Announced
Jan 18, 2024
Combined company
Qianzhi Group Holding (Cayman) Limited
IPO underwriters
PROPOSED BUSINESS Our Company
SPAC counsel (IPO)
Graubard Miller and Ogier
Underwriters' counsel (IPO)
Winston & Strawn

More on this SPAC for subscribers

Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.

Try it free for 7 daysOpen in Ticker Launch

Then $99/month or $999/year. Cancel anytime.

Filings

Other pending SPAC mergers